LUND, Sweden, Nov. 30, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB(Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that molecules in its NVP015 program have demonstrated positive effects in experimental models of genetic mitochondrial disease...
from PR Newswire: //www.prnewswire.co.uk/news-releases/neurovives-genetic-mitochondrial-disease-program-nvp015-reaches-significant-milestone-660951663.html
No comments:
Post a Comment